GLA
MYGN icon

Great Lakes Advisors’s Myriad Genetics MYGN Stock Holding History

Great Lakes Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-26,415
Closed -$555K – 383
2013
Q4 		$555K Buy
26,415
+15,778
+148% +$399K 0.03% 227
2013
Q3 		$250K Buy
+10,637
New +$302K 0.01% 330

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Great Lakes Advisors's MYGN Position: Q1 2014 in Review

Great Lakes Advisors sold out of Myriad Genetics (MYGN) in Q1 2014, closing a stake of 26,415 shares — an estimated $555K sold.

Great Lakes Advisors first reported a position in MYGN in Q3 2013 and held it in 2 quarters. The position peaked at $555K in Q4 2013. 280 funds tracked by Wall St. Rank hold MYGN as of Q1 2014.

  • Great Lakes Advisors reported no remaining Myriad Genetics position as of Q1 2014 after selling out during the quarter.
  • Great Lakes Advisors sold 26,415 Myriad Genetics shares in Q1 2014, an estimated $555K.
  • Great Lakes Advisors first reported a position in Myriad Genetics in Q3 2013 and held it in 2 quarters.
  • Great Lakes Advisors's Myriad Genetics position peaked at $555K in Q4 2013.
  • 280 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2014.

Based on Great Lakes Advisors's 13F filing for Q1 2014, filed 22 May 2014.